DEA Finalizes Rule Rescheduling State-Licensed and FDA-Approved Marijuana to Schedule III

Unlicensed bulk marijuana remains firmly entrenched in Schedule I to prevent excessive domestic production. Synthetically derived tetrahydrocannabinols, such as delta-10, are entirely excluded from this rule and remain classified as Schedule I controlled substances. Hemp, previously removed from the statutory definition of marijuana, is similarly unaffected by this regulatory shift. The rule establishes an expedited registration pathway for entities already holding active state medical marijuana licenses, allowing them to legally manufacture, distribute, and dispense medical marijuana under federal law. The Administrator is mandated to accept state credentials as conclusive evidence of state-law authorization and must process applications submitted within sixty days of the rule's publication within a six-month window. Early applicants are granted immediate safe harbor to operate under their state licenses while their federal applications are pending. If a state medical marijuana license is suspended, revoked, or expires, the corresponding federal registration is automatically suspended. Extensive compliance safe harbors have been engineered to prevent operational collapse among transitioning state licensees. Registrants utilizing the state license pathway are broadly exempted from federal labeling, packaging, sealing, physical security, and disposal requirements, provided they maintain strict compliance with their respective state laws. The lone federal mandate surviving this exemption is the required inclusion of the statutory warning label defined in 21 U.S.C. 825(c). The Administrator will accept state-required reports to the maximum extent permissible, limiting distinct federal filings only to those necessary to satisfy international treaty obligations. State-authorized medical marijuana certifications now serve as legally sufficient prescriptions for dispensing purposes, provided they include the user's details, the date of issuance, and the state license number of the authorizing practitioner. International treaty compliance necessitates a highly specific economic intervention regarding wholesale crop monopolies. To satisfy Article 23 of the Single Convention on Narcotic Drugs, the rule creates a nominal-price purchase-and-resale mechanism, requiring registered manufacturers to establish a nominal price for their marijuana crops. The Administration will formally purchase the inventory at that price and immediately sell it back to the manufacturer, adding an administrative fee. Manufacturers must maintain these crops in facilities accessible to federal inspectors on demand until this transaction clears. Importation and exportation are subject to renewed scrutiny. Because Schedule III substances fall under different statutory parameters than Schedule I, the agency amended its import and export regulations to explicitly require a federal permit for the cross-border movement of all rescheduled marijuana products. Financial and scientific realities for the industry undergo a profound shift. By removing state-licensed operators from Schedule I and II classifications, these entities are no longer subject to the severe deduction disallowances imposed by Section 280E of the Internal Revenue Code. The Acting Attorney General noted this structural change while explicitly urging the Treasury Department to consider retrospective relief for compliant state operators. Scientific researchers are granted explicit immunity, as federally registered researchers utilizing state-licensed marijuana products will incur no civil or criminal liability for sourcing their materials outside the traditional bulk manufacturing system. The Administration is barred from using the acquisition of state-licensed marijuana as a basis for adverse action against a researcher's federal registration.